Article
CSC01 shows promise as a potential inhibitor of the oncogenic G13D mutant of KRAS: an in silico approach.
Amino acids - 1 Dec 2023
Durojaye Olanrewaju Ayodeji, Ejaz Umer, Uzoeto Henrietta Onyinye, Fadahunsi Adeola Abraham, Opabunmi Adebayo Oluwole, Ekpo Daniel Emmanuel, Sedzro Divine Mensah, Idris Mukhtar Oluwaseun
Abstract excerpt
About 30% of malignant tumors include KRAS mutations, which are frequently required for the development and maintenance of malignancies. KRAS is now a top-priority cancer target as a result. After years of research, it is now understood that the oncogenic KRAS-G12C can be targeted. However, many other forms, such as the G13D mutant, are yet to be addressed. Here, we used a receptor-based pharmacophore modeling...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.